Nuestro blog

The challenges associated with conducting central nervous system clinical research all impact sponsors’ and study teams’ ability to gather stronger therapeutic evidence—but they also prime CNS studies for decentralization.

Many clinical trial sponsors don’t understand how decentralized clinical trials (DCTs) fit within today’s regulatory landscape. This lack of familiarity with decentralized research and regulatory approaches has created DCT hesitancy among sponsors.

Patient engagement in clinical trials can make or break a study. Engaged patients are more likely to participate and complete studies, which can strengthen data collection and, ultimately, provide more robust therapeutic evidence of safety and efficacy.

Clinical trials lay the foundation for breakthrough drugs, digital therapeutics, and medical devices—and, at the center of these studies are the patients.

We know that a patient-centric approach to clinical trials generally leads to higher compliance and retention rates. DCTs are more convenient for participants.

In the first of our two-part series exploring minority participation in clinical trial research, we examine the numerous challenges to securing diversity in clinical trials and the consequences of primarily white patient populations.

ObvioHealth tackles misconceptions about decentralized clinical trials, they’re less safe, they’re always fully virtual, the data isn’t trustworthy, and so on.

BYOD ePRO models deliver a range of benefits to clinical trial stakeholders, including increased engagement, reduced site team burden, and more.

Digital therapeutics are playing an increasing role in mental health care. Ensuring that these DTx products meet quality thresholds is key to effective care.